MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cara Therapeutics Company Profile (NASDAQ:CARA)

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $27.33 (43.86% upside)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetActions
8/12/2015Canaccord GenuityReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Needham & Company LLCInitiated CoverageBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015Canaccord GenuityBoost Price TargetBuy$20.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015Piper JaffrayReiterated RatingBuy$30.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/23/2015Needham & Company LLCReiterated RatingBuy$22.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/23/2015Janney Montgomery ScottBoost Price TargetFair Value$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Piper JaffraySet Price TargetBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Needham & Company LLCSet Price TargetBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2015Canaccord GenuityReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015Needham & Company LLCInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Canaccord GenuityReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Needham & Company LLCReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015MLV & Co.Initiated CoverageBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2015Canaccord GenuityInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Summer StreetInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2014Canaccord GenuityBoost Price Target$25.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2014Needham & Company LLCInitiated CoverageBuy$27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2014Stifel NicolausInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2014Canaccord GenuityInitiated CoverageBuy -> Buy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2014Janney Montgomery ScottInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2014Piper JaffrayInitiated CoverageOverweight$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/28/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha